SCHEMBL10159619

SCHEMBL10159619

FC(F)(CCBr)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TDP1 Q9NUW8 1/20 0.37
DAO P14920 1/20 0.37
PTPN1 P18031 1/20 0.37
KIF11 P52732 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA5A P35218 1/20 0.35
CA9 Q16790 1/20 0.35
KCNN4 O15554 2/20 0.35
TRPA1 O75762 1/20 0.35
CNR1 P21554 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
S1PR4 O95977 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2281974 0.80 TSHR (0.50) TSHRALDH1A1TDP1DAOPTPN1
SCHEMBL1721653 0.79 KCNN4 (0.34) PTPN1KCNN4CYP2C9CYP2C19
SCHEMBL10830860 0.77 TDP1 (0.42) TSHRALDH1A1TDP1KIF11KCNN4
SCHEMBL8380102 0.76 TSHR (0.46) TSHRALDH1A1DAOPTPN1KIF11
SCHEMBL2015017 0.76 TSHR (0.46) TSHRALDH1A1TDP1DAOPTPN1
SCHEMBL1097922 0.76 TSHR (0.46) TSHRALDH1A1DAOPTPN1KIF11
SCHEMBL10159499 0.76 KIF11 (0.50) TSHRALDH1A1KIF11CA1CA2
SCHEMBL28287845 0.75 KIF11 (0.54) TSHRALDH1A1TDP1KIF11KCNN4
SCHEMBL2009823 0.74 HDAC1 (0.36) TSHRALDH1A1MEN1KMT2A
SCHEMBL20654754 0.74 ALDH1A1 (0.44) TSHRALDH1A1TDP1KIF11TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3925945-A1 METHOD FOR PRODUCING FLUORINATED COMPOUND Daikin Industries, Ltd. (JP) 2021-12-22 EP disclosed
US-9499494-B2 Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis NORTHWESTERN UNIVERSITY (US) 2016-11-22 US disclosed
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST 2015-07-23 US disclosed
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NORTHWESTERN UNIVERSITY (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203456-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 TSHR 4741/4885ALDH1A1 3417/4885TDP1 11/4885
US-20120046309-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS NUDT1, TYMP, HPRT1 TSHR 4741/4885ALDH1A1 3417/4885TDP1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.